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http://dx.doi.org/10.1016/j.bpj.2014.04.061Bioluminescence resonance energy transfer (BRET) is
widely used to study protein oligomerization, particularly
for membrane proteins. BRET works on the principle that
excitation energy from a bioluminescent donor luciferase
(Rluc) molecule can be transferred to a fluorescent acceptor
(typically a derivative of green fluorescent protein; GFP) by
nonradiative dipole-dipole coupling, such that emission is
observed from the acceptor rather than the donor (1). The
efficiency of transfer (BRETeff) is dependent on the relative
separation distance between the two molecules, making it
informative with regard to the stoichiometry of proteins of
interest attached to the donors and acceptors.
We have previously described two BRET-based assays
that distinguish between monomers and dimers in situ (2).
The type-1 BRET assay uses the relationship between
BRETeff and acceptor/donor ratio at a constant total protein
density as an indicator of stoichiometry. The type-2 BRET
assay relies on the systematic variation of protein expression
levels, starting at very low expression levels, to identify
constitutive dimers. An alternative approach, the BRET
competition assay, is based on the principle that the extent
of BRET between donor and acceptor molecules forming
oligomeric complexes is sensitive to the presence of un-
tagged competitor proteins. These compete with acceptor-
tagged molecules for interaction with their donor-tagged
counterparts, thereby reducing the BRETeff for oligomers.
In contrast, the presence of competitors has no effect on
BRETeff for monomeric, i.e., randomly interacting proteins
(see Fig. S1, a and b, in the Supporting Material).
A key consideration in the use of BRET competition as-
says is the effect of competitor proteins on the total expres-
sion of their acceptor- and donor-tagged equivalents. The
total expression levels of many membrane proteins are strin-
gently regulated via a combination of translational regula-
tion and recycling/degradation at the cell surface (3), and
often partly regulated via negative feedback mechanisms.
In the context of BRET experiments, increasing total proteindensity at the cell surface by coexpressing competitors
could, in many cases, induce increased recycling of the pro-
teins in question, regardless of whether they are tagged or
untagged. This would lead to a reduction in the overall
density of tagged proteins, which would in turn reduce the
contribution to BRETeff of nonspecific interactions, produc-
ing a false dimer signature for a monomer (see Fig. S1, c
and d). This may also apply to the addition of closely related
competitors during investigations of heterodimers, because
they may also be subject to similar regulatory networks.
Although this issue has been appreciated for several years
(e.g., Pfleger and Eidne (1)), the potential confounding
effects of competitors on the expression of the donors and ac-
ceptors are not generally allowed-for in conventional BRET
competition assays. In some cases, BRETeff is measured at a
singleGFP/Rluc ratio in both the presence or absence of com-
petitors (4,5), whereas elsewhere cells have been transfected
with constant amounts of donor- and acceptor-encoding
DNA along with increasing amounts of competitor DNA
(6,7). Irrespective of the approach used, the decreases in
BRETeff observed upon introduction of competitor in these
studies have invariably been interpreted as indicating oligo-
merization, conclusions that will be unsafe if the competitor
alters the overall levels of expression of the tagged proteins.
Here, we show that the presence of competitor proteins can
profoundly alter the expression of tagged type-I membrane
(TM) proteins and G protein-coupled receptors (GPCRs) in
conventionalBRETcompetition assays.Wegoon to establish
an improved competition-based assay that avoids this source
of potential artifacts, which we call the type-3 BRET assay.
In experiments replicating conventional BRET competi-
tion assays,whereinBRETeff ismeasured at single expression
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of competitor proteins reduced the expression of a type I TM
protein (CD86) as well as the GPCRs b2AR (b2 adrenergic
receptor), mCannR2 (mouse cannabinoid receptor 2), and
GABAbR2 (g-amino butyric acid receptor 2) (Fig. 1). Flow
cytometry analysis revealed that this was not the result of
changes in transfection efficiency (see Fig. S2), and it is likely
instead to be caused by intrinsic signaling processes regu-
lating protein expression. The largest decreases in expression
were observed for b2AR and mCannR2, suggesting that the
expression levels of these receptors are particularly sensitive
to the presence of competitors, perhaps as the result of
increased levels of basal, stochastic signaling (8) introduced
to the cell by the unlabeled GPCRs.
Reduced BRETeff in the presence of competitor was
observed for all proteins with the exception of the known
monomer, CD2 (see Fig. S3). For the known dimers CD28
and CD80, this is likely caused by genuine displacement of
the tagged proteins from BRET-productive homodimers by
unlabeled competitors, because expression of these proteins
was unaffected by the competitors (Fig. 1). However, the
well-characterized monomer CD86 (2,9) also exhibited a
reduction inBRETeff (see Fig. S3),which is likely attributable
to decreased nonspecific interactionswithin the plasmamem-
brane as a result of its reduced protein density in the presence
of the competitor. In contrast, CD2 exhibits no change in
BRETeff and its expression level is unaltered in the presence
of competitor. It is therefore clear that conventional BRET
competition assays are subject to the confounding effects of
receptor expression changes in the presence of competitors,
and therefore cannot be relied upon to correctly distinguish
between monomers and dimers. Changes in BRETeff
observed in these assays could result from genuine competi-
tion for position in homodimers, or changes in nonspecific in-
teractions arising due to alterations in protein density.FIGURE 1 Introduction of competitor proteins can result in
reduction of tagged protein expression. Expression values
represent combined GFP and Rluc emission normalized to
Rluc emission units using the GFP/Rluc ratio. Error bars repre-
sent mean 5 SE. *p < 0.05; **p < 0.01; ***p < 0.005 (two-tailed
t-test). (Dark red) Type-I protein dimer; (dark blue) type-I protein
monomer; (pale blue/pale red) GPCR.
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competition-based assay, called the type-3 BRET assay, was
established. The basis of the new assay is that the relationship
between BRETeff and protein expression level will be unaf-
fected by the presence of competitors in the case ofmonomers,
but will change for dimers, such that lower BRETeff will be
observed at the same expression level (see Fig. S1 b). By
measuring BRETeff at systematically varied expression levels
it should, in principle, be possible to distinguish between
genuine and apparent dimers. Moreover, because a range of
expression levels are used in this assay, it shouldbemore easily
interpretable than some conventional BRET competition
assays in which attempts were made to achieve a single, con-
stant protein density. To test this, BRETeff was measured for
C-terminally taggedCD2,CD86,CD28, andCD80at different
expression levels in human embryonic kidney 293T cells. The
expression level was varied by incubating cells transfected
simultaneously for various lengths of time posttransfection,
as previously described for type-2 BRETassays (2). Transfec-
tion was performed using DNA encoding the untagged, GFP-
tagged, and Rluc-tagged forms of the protein of interest in the
ratio 26:12:1, because this equates to a 2:1 DNA ratio of
untagged to tagged protein, and ensures that an excess of
GFP-tagged over Rluc-tagged protein maximizes BRETeff.
For cells in which no competitor was expressed, DNA encod-
ing the untaggedproteinwas replacedwith the samevector but
encoding no protein, to ensure equivalent transfection condi-
tions for all cells (see the Supporting Material).
In the new assay, both CD28 and CD80 gave significantly
lower BRETeff values at a given expression level in the pres-
ence of competitor (Fig. 2 a). In addition to this change in
BRETeff/expression relationship for CD28 and CD80, both
proteins gave data with a lower BRETeff y-intercept in the
presence of competitor, consistent with an increase in the
apparent monomeric behavior (2). In contrast, neither CD2
nor CD86 exhibited any change in BRETeff/expression rela-
tionship in the presence of competitor (Fig. 2 b), consistent
with the predicted behavior for monomers. In all cases, the
GFP/Rluc ratio remained constant across varying protein den-
sities independent of the presence of competitor (see Fig. S4).
To determine whether the assay was capable of identifying
GPCRdimers, it was applied toGABAbR2, a heterodimer sub-
unit that homodimerizeswhenexpressed alone (e.g., (2,10,11)).
In the type-3BRETassay,GABAbR2yielded significant differ-
ences in the BRETeff/expression relationship in the presence
and absence of competitor (Fig. 2 c), consistent with dimeric
behavior. Conversely, application of the type-3 assay to b2AR
and mCannR2 yielded data consistent with monomeric be-
havior (Fig. 2 c). This is in agreement with our previous obser-
vations that these GPCRs behave as monomers in both type-1
and type-2 assays (2). Possible explanations for the disagree-
ment between these observations and previous BRET-based
studies of b2AR have been discussed elsewhere (2,12).
In conclusion, these data confirm that conventional BRET
competition assays are prone to artifacts that are readily
FIGURE 2 Application of type-3 BRET to type-I TM proteins and
GPCRs. Reduced BRETeff at a given expression level was
observed for the dimers CD28, CD80, and GABAbR2 in the pres-
ence of competitor (A and C), but not for the monomers CD2 and
CD86 (B). TheGPCRsmCannR2andb2ARdidnotexhibita change
in BRETeff/expression relationship upon addition of competitor
(C). Data are combined from three independent experiments in
all cases except CD86, which constitutes four experiments.
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ularly significant in relation to BRET-based studies of GPCR
stoichiometry, because our data suggest that these types of re-
ceptors may be particularly susceptible to regulated expression
in the presence of higher densities of receptors expressed ascompetitors. It is difficult to estimate the extent to which the
interpretation ofpreviousBRETcompetition studies ofGPCRs
and othermembrane proteinsmay have been influenced by this
effect, but it seems likely to have been a factor in at least some
studies. Type-3 BRETassays ought to serve as a useful adjunct
to existing BRET assays (2). It has the advantage over type-2
BRET assays, in which expression is varied for fixed ratios of
acceptors and donors, of not being dependent on very low
expression levels, making it the more flexible assay.SUPPORTING MATERIAL
SupportingMethods,with subsectionsCloningofBRETConstructs, FlowCy-
tometry, and BRETAssays, plus four equations and four figures, are available
at http://www.biophysj.org/biophysj/supplemental/S0006-3495(14)00527-X.ACKNOWLEDGMENTS
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